Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T36644 |
Rezivertinib
|
Others | Others |
Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI) with potent activity against both common activation EGFR and resistance T790M mutations. Additionally, Rezivertinib demonstrates excellent central nervous system (CNS) penetration and exhibits antitumor activity[1][2]. | |||
T74641 |
Rezivertinib analogue 1
|
Others | Others |
Rezivertinib analogue 1 是一种甲磺酸奥希替尼的工艺杂质, 可用于非小细胞肺癌的研究。 |